{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T17:23:12Z","timestamp":1720113792677},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,7,29]],"date-time":"2012-07-29T00:00:00Z","timestamp":1343520000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s12288-012-0177-4","type":"journal-article","created":{"date-parts":[[2012,7,28]],"date-time":"2012-07-28T13:01:10Z","timestamp":1343480470000},"page":"147-151","source":"Crossref","is-referenced-by-count":2,"title":["Bortezomib, Dexamethasone, and High-Dose Melphalan as Conditioning for Stem Cell Transplantation in Young Japanese Multiple Myeloma Patients: A Pilot Study"],"prefix":"10.1007","volume":"29","author":[{"given":"Naoki","family":"Takezako","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Sekiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihisa","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiho","family":"Homma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Noto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiyoshi","family":"Miwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,29]]},"reference":[{"key":"177_CR1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE et al (2003) Review of 1,027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21\u201333","journal-title":"Mayo Clin Proc"},{"key":"177_CR2","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","volume":"111","author":"RA Kyle","year":"2008","unstructured":"Kyle RA, Rajkumar SV (2008) Multiple myeloma. Blood 111:2962\u20132972","journal-title":"Blood"},{"key":"177_CR3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau J-L, Stoppa AM et al (1996) A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335:91\u201397","journal-title":"N Engl J Med"},{"key":"177_CR4","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","volume":"92","author":"JP Fermand","year":"1998","unstructured":"Fermand JP, Ravaud P, Chevret S et al (1998) High dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: upfront or rescue treatment? results of a multicentric sequential randomized trial. Blood 92:3131\u20133136","journal-title":"Blood"},{"key":"177_CR5","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1182\/blood-2009-08-238196","volume":"115","author":"J Blad\u00e9","year":"2010","unstructured":"Blad\u00e9 J, Rosi\u00f1ol L, Cibeira MT, Rovira M, Carreras E (2010) Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 115:3655\u20133663","journal-title":"Blood"},{"key":"177_CR6","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.2006.06271.x","volume":"135","author":"B Barlogie","year":"2006","unstructured":"Barlogie B, Tricot GJ, Anaissie E et al (2006) Long term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 135:158\u2013164","journal-title":"Br J Haematol"},{"key":"177_CR7","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2009-03-201053","volume":"114","author":"J-L Harousseau","year":"2009","unstructured":"Harousseau J-L, Attal M, Avet-Loiseau H (2009) The role of complete response in multiple myeloma. Blood 114:3139\u20133146","journal-title":"Blood"},{"key":"177_CR8","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1200\/JCO.2008.21.1060","volume":"27","author":"JL Harousseau","year":"2009","unstructured":"Harousseau JL, Avet-Loiseau H, Attal M et al (2009) Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high dose therapy. J Clin Oncol 27:5720\u20135726","journal-title":"J Clin Oncol"},{"key":"177_CR9","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood-2009-09-241737","volume":"115","author":"A Palumbo","year":"2010","unstructured":"Palumbo A, Bringhen S, Bruno B et al (2010) Melphalan 200\u00a0mg\/m2 versus melphalan 100\u00a0mg\/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood 115:1873\u20131879","journal-title":"Blood"},{"key":"177_CR10","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609\u20132617","journal-title":"N Engl J Med"},{"key":"177_CR11","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487\u20132498","journal-title":"N Engl J Med"},{"key":"177_CR12","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.2005.03.2383","volume":"24","author":"JR Berenson","year":"2006","unstructured":"Berenson JR, Yang HH, Sadler K et al (2006) Phase I\/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 24:937\u2013944","journal-title":"J Clin Oncol"},{"key":"177_CR13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2009-06-229658","volume":"115","author":"M Rousse","year":"2010","unstructured":"Rousse M, Moreau P, Huynh A et al (2010) Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Mye\u2032lome (IFM). Blood 115:32\u201337","journal-title":"Blood"},{"key":"177_CR14","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1158\/1078-0432.CCR-10-1662","volume":"16","author":"S Lonial","year":"2010","unstructured":"Lonial S, Kaufman J, Tighiouart M et al (2010) A phase I\/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clin Cancer Res 16:5079\u20135086","journal-title":"Clin Cancer Res"},{"key":"177_CR15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.5045\/kjh.2010.45.3.183","volume":"45","author":"SR Lee","year":"2010","unstructured":"Lee SR, Kim SJ, Park Y, Sung HJ, Choi CW, Kim BS (2010) Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma. Korean J Hematol 45:183\u2013187","journal-title":"Korean J Hematol"},{"key":"177_CR16","doi-asserted-by":"crossref","first-page":"813","DOI":"10.4065\/77.8.813","volume":"77","author":"SV Rajkumar","year":"2002","unstructured":"Rajkumar SV, Gertz MA, Kyle RA et al (2002) Current therapy for multiple myeloma. Mayo Clin Proc 77:813\u2013822","journal-title":"Mayo Clin Proc"},{"key":"177_CR17","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","volume":"16","author":"Myeloma Trialists\u2019 Collaborative Group","year":"1998","unstructured":"Myeloma Trialists\u2019 Collaborative Group (1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16:3832\u20133842","journal-title":"J Clin Oncol"},{"key":"177_CR18","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood.V80.4.887.887","volume":"80","author":"R Alexanian","year":"1992","unstructured":"Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B (1992) Primary dexamethasone treatment of multiple myeloma. Blood 80:887\u2013890","journal-title":"Blood"},{"key":"177_CR19","first-page":"929","volume":"91","author":"S Jagannath","year":"2006","unstructured":"Jagannath S, Richardson PG, Barlogie B et al (2006) Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and\/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 91:929\u2013934","journal-title":"Haematologica"},{"key":"177_CR20","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","volume":"121","author":"The International Myeloma Working Group","year":"2003","unstructured":"The International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121:749\u2013757","journal-title":"Br J Haematol"},{"key":"177_CR21","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie BGM, Harousseau J-L, Miguel JS et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467\u20131473","journal-title":"Leukemia"},{"key":"177_CR22","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842\u2013854","journal-title":"Cancer"},{"key":"177_CR23","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412\u20133420","journal-title":"J Clin Oncol"},{"key":"177_CR24","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/sj.bmt.1702167","volume":"25","author":"KR Desikan","year":"2000","unstructured":"Desikan KR, Tricot G, Dhodapkar M et al (2000) Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. Bone Marrow Transplant 25:483\u2013487","journal-title":"Bone Marrow Transplant"},{"key":"177_CR25","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"P Moreau","year":"2002","unstructured":"Moreau P, Facon T, Attal M et al (2002) Comparison of 200\u00a0mg\/m2 melphalan and 8\u00a0Gy total body irradiation plus 140\u00a0mg\/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 99:731\u2013735","journal-title":"Blood"},{"key":"177_CR26","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/cncr.20294","volume":"100","author":"A Aleman","year":"2004","unstructured":"Aleman A, Ayers G, Donato M et al (2004) Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer 100:2607\u20132612","journal-title":"Cancer"},{"key":"177_CR27","first-page":"3071","volume":"61","author":"T Hideshima","year":"2001","unstructured":"Hideshima T, Richardson P, Chauhan D et al (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071\u20133076","journal-title":"Cancer Res"},{"key":"177_CR28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","volume":"127","author":"S Jagannath","year":"2004","unstructured":"Jagannath S, Barlogie B, Berenson J et al (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127:165\u2013172","journal-title":"Br J Haematol"},{"key":"177_CR29","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood-2010-08-300863","volume":"117","author":"P Moreau","year":"2011","unstructured":"Moreau P, Attal M, P\u00e9gouri\u00e9 B et al (2011) Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005\u201301 trial. Blood 117:3041\u20133044","journal-title":"Blood"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-012-0177-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12288-012-0177-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-012-0177-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T16:02:16Z","timestamp":1594483336000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12288-012-0177-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,29]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["177"],"URL":"https:\/\/doi.org\/10.1007\/s12288-012-0177-4","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"value":"0971-4502","type":"print"},{"value":"0974-0449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,29]]}}}